Gertrude Biomedical at a glance

 

Gertrude Biomedical is developing innovative drugs that target multiple mechanisms responsible for the growth and spread of many poorly treated cancers.

Our target is a transcription factor in the cell nucleus called SOX18 which regulates gene pathways to manipulate multiple hallmarks of cancer.
Gertrude Biomedical PPT_v7_Large.jpg
We are developing drugs to treat two indications of significant unmet need, Kaposi Sarcoma and Angiosarcoma, whose pathologies involve multiple SOX18-dependent pathways.
 
SOX18’s ability to target several cellular processes translates to significant commercial and clinical potential beyond orphan indications.